Dynamics of neoantigen-specific T-cells in post-transplant relapse: do leukemia neoantigens elicit immune responses in transplant recipients?

COI Statement

Competing interests: The authors declare no competing interests. Ethics approval and consent to participate: Informed consent was obtained for the research use of biospecimen in compliance with the Declaration of Helsinki under the protocols approved by the Institutional Review Board at the National Heart, Lung, and Blood Institute (Clinicaltrial.gov: NCT02226861) or the University of Pittsburgh (HCC Protocol 18-183).

References:

• Peri A, Salomon N, Wolf Y, Kreiter S, Diken M, Samuels Y. The landscape of T cell antigens for cancer immunotherapy. Nat Cancer. 2023;4:937–54. https://doi.org/10.1038/s43018-023-00588-x .
• Forghieri F, Riva G, Lagreca I, Barozzi P, Vallerini D, Morselli M, et al. Characterization and dynamics of specific T cells against nucleophosmin-1 (NPM1)-mutated peptides in patients with NPM1-mutated acute myeloid leukemia. Oncotarget. 2019;10:869–82. https://doi.org/10.18632/oncotarget.26617 .
• Hofmann S, Gotz M, Schneider V, Guillaume P, Bunjes D, Dohner H, et al. Donor lymphocyte infusion induces polyspecific CD8(+) T-cell responses with concurrent molecular remission in acute myeloid leukemia with NPM1 mutation. J Clin Oncol. 2013;31:e44–7. https://doi.org/10.1200/JCO.2011.41.1116 .
• Narayan R, Niroula A, Wang T, Kuxhausen M, He M, Meyer E, et al. HLA Class I Genotype Is Associated with Relapse Risk after Allogeneic Stem Cell Transplantation for NPM1-Mutated Acute Myeloid Leukemia. Transplant Cell Ther. 2023;29:452.e451–452.e411. https://doi.org/10.1016/j.jtct.2023.03.027 .
• Hundal J, Carreno BM, Petti AA, Linette GP, Griffith OL, Mardis ER, et al. pVAC-Seq: A genome-guided in silico approach to identifying tumor neoantigens. Genome Med. 2016;8:11. https://doi.org/10.1186/s13073-016-0264-5 .